News

At the 2024 San Antonio Breast Cancer Symposium (SABCS), new Phase III trial data presented the promising results of imlunestrant, an oral next-generation selective estrogen receptor degrader (SERD), in patients with advanced breast cancer.

Daily glucocorticoid hormones, commonly prescribed to reduce inflammation, can significantly influence the progression of glioblastoma (GBM), the most aggressive brain cancer in adults, according to new research.

A recent study examining real-world COPD treatment outcomes has highlighted safety concerns regarding single-inhaler triple therapy compared to the long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination, particularly in terms of cardiovascular risks.

New research offers insights into medical factors linked to the absence of Alzheimer’s disease neuropathologic changes (ADNC) in individuals aged 90 and older.

Patients with high-risk, BRCA-positive breast cancer receiving the PARP inhibitor olaparib after standard treatment continue to experience significant survival benefits, according to 6-year follow-up results from the Phase III OlympiA trial.

Navigating treatment options for hidradenitis suppurativa (HS) may include consideration of clinic-based deroofing as a more effective and economical choice compared to local excision.

Immune thrombocytopenic purpura (ITP), an autoimmune disorder causing dangerously low platelet counts, is rarely associated with cytomegalovirus (CMV) infection in otherwise healthy individuals.

According to a new study, achieving sustained drug-free remission (SDFR) in giant cell arteritis (GCA) is possible for a significant subset of patients, with low relapse rates once remission is reached.